From baseline data in the entire cohort, it can be assumed that women in the control group had a more advanced cancer with worse prognosis compared with those who have undergone COS, based on the more advanced T-stage and hormonal receptor sensitivity. This evidence concerns the gene NR4A1 and cancer.